Meeting
2017 Genitourinary Cancers Symposium
Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Aseem Anand
Memorial Sloan Kettering Cancer Center, New York, NY
Aseem Anand , Anders Bjartell , Daniel Costin Danila , Danny Francisco Martinez , Lars Edenbrandt , Steven M. Larson , Howard I. Scher , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 170)
DOI
10.1200/JCO.2017.35.6_suppl.170
Abstract #
170
Poster Bd #
F24
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2021 Genitourinary Cancers Symposium
18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.
First Author: Pedro C. Barata
Poster
2018 Genitourinary Cancers Symposium
Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.
First Author: Maarten Johannes van der Doelen